Osteoporosis Drug Market to Grow to US$14 billion by 2014.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46468) has announced the addition of Espicom Business Intelligence's new report: New Drug Futures: Musculoskeletal musculoskeletal /mus·cu·lo·skel·e·tal/ (-skel´e-t'l) pertaining to or comprising the skeleton and muscles. mus·cu·lo·skel·e·tal adj. Relating to or involving the muscles and the skeleton. Chapter to their offering. Please note this chapter is taken from the "New Drug Futures" report. This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the musculoskeletal sector. The report includes unique sales forecasts by major product. The musculoskeletal market is the sixth largest therapeutic category by sales and generated over US$228 billion (+0.8% YoY) in 2005. Sales grew strongly in the US and Europe which accounted for 54% and 23% of sales however, sales have slowed significantly, largely due to the withdrawal of a number of COX-2 inhibitors Cox-2 Inhibitors Definition Cox-2 inhibitors are non-steroidal anti-inflammatory drugs (NSAIDs) which selectively inhibit cyclooxygenase-2. The cyclooxygenases are required for the creation of prostaglandins. during 2004 and early 2005. Two of the largest segments of the musculoskeletal market are rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. (anti-rheumatics) and osteoporosis (bone calcium regulators). The remaining sales are derived from the treatment of a mixture of aetiologies such as anti-inflammatory conditions and muscle relaxants Muscle Relaxants Definition Skeletal muscle relaxants are drugs that relax striated muscles (those that control the skeleton). They are a separate class of drugs from the muscle relaxant drugs used during intubations and surgery to reduce the need for . ANTI-RHEUMATOID DRUG SALES We estimate the rheumatoid arthritis (RA) market was worth around US$5.9 billion in 2005 and is expected to reach nearly US$7 billion by 2008 and over US$9 billion by 2013. Rheumatoid arthritis was estimated to affect more than 21 million people worldwide in 2004. According to the American College of Rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc. rheu·ma·tol·o·gy n. , approximately two million US citizens suffer from RA where around 75% are women with a peak age group of between 20 and 45 years old. Rheumatoid arthritis is a progressive, systemic autoimmune disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma characterised by inflammation of the membrane lining in joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. In more severe cases of RA the eyes, lungs or blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. may be involved. RA may also shorten life expectancy by affecting major organ systems and after 10 years, less than 50% of patients can function normally. OSTEOPOROSIS We forecast the osteoporosis market was worth nearly US$6 billion in 2005, with around 80% of sales being derived in the US. It has been forecast to be worth between US$8-10 billion by 2010 and nearly US$14 billion by 2014. Osteoporosis was estimated to affect approximately 100 million people worldwide in 2005. Approximately eight million US women are estimated to have osteoporosis and 22 million are at risk of the disease. Answering key business questions - J&J/Schering Plough could have a winner with CNTO CNTO China National Tourist Office 148 for rheumatoid arthritis, but how will it fare against competitive products from Roche and Celltech/UCB? - TAP's novel xanthine oxidase inhibitor marks a new approach to the treatment of gout gout, condition that manifests itself as recurrent attacks of acute arthritis, which may become chronic and deforming. It results from deposits of uric acid crystals in connective tissue or joints. and shows clinical benefits over the generically available allopurinol allopurinol /al·lo·pur·i·nol/ (al?o-pur´i-nol) an isomer of hypoxanthine, capable of inhibiting xanthine oxidase and thus of reducing serum and urinary levels of uric acid; used in prophylaxis and treatment of hyperuricemia and uric acid . With no direct competition prospects are good - so what are its projected sales over the next 6 years? - Amgen's osteoporosis treatment denosumab, currently in Phase III, could be the first to market in a new class of fully-humanised MAb therapies. But with a highly- competitive market and a number of regulatory hurdles to cross, what are its chances of launch? This chapter covers: Current Market Size Addressable Patient Population Current Treatments Sales Drivers Sales Breakers Future Treatments - Early Stage Market Dynamics - Winners and Losers Key launches to 2011 Competitor Ratio Analysis - Products Competitor Ratio Analysis - Companies CURRENT MARKET SIZE ANTI-RHEUMATIC DRUG SALES ANTI-OSTEOPOROSIS DRUG SALES ADDRESSABLE PATIENT POPULATION RHEUMATOID ARTHRITIS OSTEOPOROSIS CURRENT TREATMENTS RHEUMATOID ARTHRITIS SALES DRIVERS OSTEOPOROSIS SALES DRIVERS RHEUMATOID ARTHRITIS SALES BREAKERS OSTEOPOROSIS SALES BREAKERS FUTURE TREATMENTS MARKET DYNAMICS - WINNERS & LOSERS KEY DRUGS LAUNCHES BY 2010 KEY EVALUATION CRITERIA KEY MUSCULOSKELETAL DRUG LAUNCHES BY 2010 Actemra (Roche/Chugai) Bazedoxifene (Wyeth) Cimzia (UCB/Celltech) CNTO 148 (Johnson & Johnson/Schering-Plough) Denosumab (Amgen) Entereg (GlaxoSmithKline/Adolor) Febuxostat (TAP Pharmaceutical Products) Orencia (Bristol-Myers Squibb) Preos (NPS NPS National Park Service NPS Naval Postgraduate School NPS Net Promoter Score (customer management) NPS Non-Point Source pollution NPS Native Plant Society NPS Norfolk Public Schools (Virginia) Pharmaceuticals) For more information visit http://www.researchandmarkets.com/reports/c46468 Source: Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion